KV Pharma, ex-chief wrestle over roots of 2008 crisis

How to explain KV Pharmaceuticals' sudden skid in 2008? The company has one version, and ex-CEO Mark Hermelin has another--and that's the gist of the ongoing court fight. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.